LakeShore Biopharma Announces Leadership Transitions
LakeShore Biopharma (Nasdaq: LSB) has announced significant leadership transitions effective September 1, 2024. Xu Wang, previously Chief Operation Officer, has been appointed as the new Chief Executive Officer, succeeding Dave Chenn and Dr. Hui Shao. Dr. Shao transitions to the role of Chief Business Officer, focusing on global strategic planning and transactions. Additionally, he has been appointed as Vice Chairman of the Board.
Rachel Yu, formerly Interim Chief Financial Officer, has been promoted to Chief Financial Officer. She also maintains her role as a partner at Oceanpine Capital's healthcare practice. Xu Wang joins the company's Board of Directors as a new member. These changes aim to strengthen LakeShore Biopharma's leadership team as it continues its mission in developing vaccines and therapeutic biologics for infectious diseases and cancer.
LakeShore Biopharma (Nasdaq: LSB) ha annunciato importanti transizioni di leadership che entreranno in vigore il 1 settembre 2024. Xu Wang, precedentemente Chief Operating Officer, è stato nominato nuovo Chief Executive Officer, succedendo a Dave Chenn e al Dr. Hui Shao. Il Dr. Shao passerà al ruolo di Chief Business Officer, concentrandosi sulla pianificazione strategica globale e sulle transazioni. Inoltre, è stato nominato anche Vice Presidente del Consiglio.
Rachel Yu, in precedenza Chief Financial Officer ad interim, è stata promossa a Chief Financial Officer. Mantiene anche il suo ruolo di partner nella divisione sanitaria di Oceanpine Capital. Xu Wang entra a far parte del Consiglio di Amministrazione dell'azienda come nuovo membro. Questi cambiamenti mirano a rafforzare il team di leadership di LakeShore Biopharma mentre continua la sua missione nello sviluppo di vaccini e biologici terapeutici per malattie infettive e tumori.
LakeShore Biopharma (Nasdaq: LSB) ha anunciado importantes transiciones de liderazgo que entrarán en vigor el 1 de septiembre de 2024. Xu Wang, anteriormente Director de Operaciones, ha sido nombrado nuevo Director Ejecutivo, sucediendo a Dave Chenn y al Dr. Hui Shao. El Dr. Shao pasará al rol de Director de Negocios, enfocándose en la planificación estratégica global y transacciones. Además, ha sido nombrado Vicepresidente de la Junta.
Rachel Yu, anteriormente Directora Financiera Interina, ha sido ascendido a Directora Financiera. También mantiene su rol como socia en la práctica de salud de Oceanpine Capital. Xu Wang se une a la Junta Directiva de la compañía como nuevo miembro. Estos cambios tienen como objetivo fortalecer el equipo de liderazgo de LakeShore Biopharma mientras continúa su misión de desarrollar vacunas y biológicos terapéuticos para enfermedades infecciosas y cáncer.
LakeShore Biopharma (Nasdaq: LSB)는 2024년 9월 1일 부터 시행되는 중요한 리더십 전환을 발표했습니다. Xu Wang은 이전에 COO로 재직했으며, 새로운 CEO로 임명되어 Dave Chenn과 Dr. Hui Shao를 이어받습니다. Dr. Shao는 Chief Business Officer의 역할로 전환되어 글로벌 전략 계획과 거래에 집중할 것입니다. 또한 이사회 부회장으로도 임명되었습니다.
Rachel Yu는 이전에 임시 CFO였으며, CFO로 승진했습니다. 그녀는 또한 Oceanpine Capital의 헬스케어 부문에서 파트너로서의 역할을 유지하고 있습니다. Xu Wang은 회사 이사회에 새로운 멤버로 합류합니다. 이러한 변화는 LakeShore Biopharma의 리더십 팀을 강화하여 감염병 및 암을 위한 백신 및 치료 생물학 개발의 사명을 계속하기 위한 것입니다.
LakeShore Biopharma (Nasdaq: LSB) a annoncé d'importantes transitions de leadership qui prendront effet le 1er septembre 2024. Xu Wang, anciennement Directeur des opérations, a été nommé nouveau Directeur général, succédant à Dave Chenn et Dr. Hui Shao. Dr. Shao passe au rôle de Directeur commercial, se concentrant sur la planification stratégique mondiale et les transactions. De plus, il a été nommé Vice-président du Conseil.
Rachel Yu, auparavant Directrice financière par intérim, a été promue au poste de Directrice financière. Elle conserve également son rôle de partenaire dans la pratique de la santé d'Oceanpine Capital. Xu Wang rejoint le Conseil d'administration de l'entreprise en tant que nouveau membre. Ces changements visent à renforcer l'équipe de direction de LakeShore Biopharma alors qu'elle poursuit sa mission de développement de vaccins et de biologiques thérapeutiques pour les maladies infectieuses et le cancer.
LakeShore Biopharma (Nasdaq: LSB) hat bedeutende Führungswechsel bekannt gegeben, die am 1. September 2024 in Kraft treten. Xu Wang, zuvor Chief Operating Officer, wurde zum neuen Chief Executive Officer ernannt und folgt damit Dave Chenn und Dr. Hui Shao nach. Dr. Shao wechselt in die Rolle des Chief Business Officer und konzentriert sich auf globale strategische Planung und Transaktionen. Darüber hinaus wurde er auch zum Vizepräsidenten des Vorstands ernannt.
Rachel Yu, vorherige Interim Chief Financial Officer, wurde zur Chief Financial Officer befördert. Außerdem behält sie ihre Rolle als Partnerin in der Gesundheitsabteilung von Oceanpine Capital. Xu Wang tritt als neues Mitglied in den Vorstand des Unternehmens ein. Diese Veränderungen zielen darauf ab, das Führungsteam von LakeShore Biopharma zu stärken, während es seine Mission fortsetzt, Impfstoffe und therapeutische Biologika für Infektionskrankheiten und Krebs zu entwickeln.
- Appointment of experienced Xu Wang as new CEO
- Promotion of Rachel Yu to permanent CFO position
- Dr. Hui Shao's transition to Chief Business Officer, focusing on global strategy
- Strengthening of the Board with new appointments
- Potential disruption due to multiple simultaneous leadership changes
- Departure of previous Interim CEO and Co-CEO from their roles
The Board has also approved the appointment of Dr. Hui Shao as the Chief Business Officer of the Company, responsible for global strategic planning and global transactions, and the transition of Ms. Rachel Yu from the role of Interim Chief Financial Officer to Chief Financial Officer of the Company. Ms. Yu is also a partner at Oceanpine Capital's healthcare practice since December 2021, where she is responsible for formulating the overall investment strategies in the healthcare sector and taking principal leadership responsibility in post-investment management of portfolio companies.
In addition to these leadership transitions, the Company also announced the appointment of Dr. Hui Shao as the Vice Chairman of the Board, and the appointment of Mr. Xu Wang as a new member of the Board. The leadership transitions and board appointments became effective on September 1, 2024.
About LakeShore Biopharma
LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The Company operates in
Investor Relations Contact
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: LakeShoreBiopharma.IR@icrinc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-leadership-transitions-302237903.html
SOURCE LakeShore Biopharma Co., Ltd.
FAQ
Who is the new CEO of LakeShore Biopharma (LSB)?
What is Dr. Hui Shao's new role at LakeShore Biopharma (LSB)?
When did the leadership transitions at LakeShore Biopharma (LSB) take effect?
Who is the new Chief Financial Officer of LakeShore Biopharma (LSB)?
